INTACT THERAPEUTICS
Topical therapeutic for ulcerative colitis combining a PXR agonist microbial metabolite with a thermosensitive delivery platform for distal colon targeting
- Sector
- Biotech
- Headquarters
- Hayward, CA
- Total capital
- $1.8M
- Federal grants
- $1.8M
- 4 awards · 2020–2024
- Rank in peer group#161 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Federal grantNSF · Phase II · SBIR Phase II: A thermogel-based drug delivery platform for the upper gastrointestinal bleeding treatment$1.0M
- Federal grantHealth and Human S · Phase I · A novel thermogel for topical treatment of ulcerative colitis with microbialmetabolite mimicry.$296K
- Federal grantHealth and Human S · Phase I · A novel thermogel for topical treatment of ulcerative colitis with microbialmetabolite mimicry.$296K
- Federal grantNSF · Phase I · SBIR Phase I: A thermogel-based drug delivery platform for the upper gastrointestinal bleeding treatment$245K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#161 · top 49%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 9- PendingMesalamine Pharmaceutical Formulations And Methods Of Use ThereofUSPTOApplication 18832003
- PendingCompositions And Methods For Treatment Of Gastrointestinal BleedingUSPTOApplication 17920897
- PendingDosing Methods For Treating Inflammatory Bowel ConditionsUSPTOApplication 17324316
Show all 9 patent records
- Mesalamine Pharmaceutical Formulations And Methods Of Use ThereofMar 20, 2025 · Application 18832003Pending
- Compositions And Methods For Treatment Of Gastrointestinal BleedingJun 15, 2023 · Application 17920897Pending
- Dosing Methods For Treating Inflammatory Bowel ConditionsNov 25, 2021 · Application 17324316Pending
- Dosing Methods For Treating Inflammatory Bowel ConditionsNov 25, 2021 · Application 16881375Pending
- Mesalamine Pharmaceutical Formulations And Methods Of Use ThereofApplication PCTUS2023012410Pending
- Compositions And Methods For Treatment Of Gastrointestinal BleedingApplication PCTUS2021028073Pending
- Compositions And Methods For Treatment Of Gastrointestinal BleedingApplication 63014874Pending
- Dosing Methods For Treating Inflammatory Bowel ConditionsApplication 63028771Pending
- Compositions And Uses Of Mesalamine ThermogelApplication 63306942Pending
Related companies, and why
- PHENOTARGET BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
- ABILITY DYNAMICS, L.L.C.Similar federal contract value in Biotech · null in contracts
- PATHOVAX LLCSimilar federal contract value in Biotech · null in contracts
- KEVIRX INC.Similar federal contract value in Biotech · null in contracts
- General Folders Inc.Similar federal contract value in Biotech · null in contracts
- APC BIO INNOVATIONS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .